同濟堂(600090.SH)股價異動:未涉及熱點概念事項
格隆匯2月5日丨同濟堂(600090.SH)公佈,公司股票於2020年2月3日、2月4日、2月5日連續三個交易日內日收盤價格漲幅偏離值累計超過20%,屬於交易異常波動。經公司自查及發函詢問公司控股股東和實際控制人,不存在應披露而未披露的重大事項。
公司主營藥品、醫療器械、保健品、保健食品等的批發零售;醫藥健康產業領域的投資;日用品、化粧品、衞生材料的批發零售等。主要通過自有營銷網絡從事藥品、器械、保健品、保健食品及其他健康相關商品等銷售業務。目前,公司主營業務未發生重大變化。
公司近期不存在可能或已經對上市公司股票交易價格產生影響的媒體報道或市場傳聞,未涉及熱點概念事項。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.